Cipher Pharmaceuticals 향후 성장

Future 기준 점검 2/6

Cipher Pharmaceuticals (는) 각각 연간 7.3% 및 9.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 6.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.1% 로 예상됩니다.

핵심 정보

7.3%

이익 성장률

6.32%

EPS 성장률

Pharmaceuticals 이익 성장	58.6%
매출 성장률	9.9%
향후 자기자본이익률	13.13%
애널리스트 커버리지	Low
마지막 업데이트	07 Nov 2025

최근 향후 성장 업데이트

Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 09

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

Recent updates

Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 09

These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively

Oct 10

Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up

Aug 29

We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings

May 16

Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable

May 09

Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?

Apr 28

Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence

Feb 23 Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Dec 13

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Nov 14

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Nov 12

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18

이익 및 매출 성장 예측

TSX:CPH - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	67	21	N/A	32	2
12/31/2026	56	17	N/A	21	3
12/31/2025	51	17	0	30	3
9/30/2025	50	17	30	30	N/A
6/30/2025	48	12	-59	21	N/A
3/31/2025	40	9	-59	21	N/A
12/31/2024	33	12	-60	20	N/A
9/30/2024	26	16	-67	13	N/A
6/30/2024	22	23	17	17	N/A
3/31/2024	22	23	14	14	N/A
12/31/2023	21	20	16	16	N/A
9/30/2023	21	32	15	15	N/A
6/30/2023	20	28	13	13	N/A
3/31/2023	20	27	13	13	N/A
12/31/2022	21	27	11	11	N/A
9/30/2022	22	10	15	15	N/A
6/30/2022	21	8	11	11	N/A
3/31/2022	22	9	11	11	N/A
12/31/2021	22	8	14	14	N/A
9/30/2021	22	5	14	14	N/A
6/30/2021	23	6	12	12	N/A
3/31/2021	21	3	11	11	N/A
12/31/2020	22	4	11	12	N/A
9/30/2020	21	7	7	7	N/A
6/30/2020	22	3	10	11	N/A
3/31/2020	23	4	11	12	N/A
12/31/2019	22	3	7	8	N/A
9/30/2019	23	-1	6	8	N/A
6/30/2019	22	2	N/A	6	N/A
3/31/2019	23	3	N/A	2	N/A
12/31/2018	23	1	N/A	8	N/A
9/30/2018	28	6	N/A	13	N/A
6/30/2018	34	9	N/A	18	N/A
3/31/2018	37	11	N/A	19	N/A
12/31/2017	40	11	N/A	13	N/A
9/30/2017	34	7	N/A	11	N/A
6/30/2017	32	5	N/A	9	N/A
3/31/2017	31	1	N/A	10	N/A
12/31/2016	30	4	N/A	11	N/A
9/30/2016	33	6	N/A	8	N/A
6/30/2016	34	2	N/A	7	N/A
3/31/2016	34	1	N/A	7	N/A
12/31/2015	34	2	N/A	8	N/A
9/30/2015	32	3	N/A	12	N/A
6/30/2015	30	13	N/A	16	N/A
3/31/2015	30	18	N/A	19	N/A
12/31/2014	29	19	N/A	25	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CPH 의 연간 예상 수익 증가율(7.3%)이 saving rate(2.8%)보다 높습니다.

수익 vs 시장: CPH 의 연간 수익(7.3%)이 Canadian 시장(11.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: CPH 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: CPH 의 수익(연간 9.9%)이 Canadian 시장(연간 4.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: CPH 의 수익(연간 9.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CPH의 자본 수익률은 3년 후 13.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/19 20:13
종가	2025/11/19 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cipher Pharmaceuticals Inc.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Tania Armstrong-Whitworth	Canaccord Genuity
Prakash Gowd	CIBC Capital Markets
David Novak	Cormark Securities Inc.

Cipher Pharmaceuticals 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 13% to CA$17.90

Price target decreased by 7.0% to CA$15.65

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 7.4% to CA$17.37

Recent updates

Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results

Third quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025

These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively

Interim CEO & Chairman of the Board exercised options to buy CA$1.3m worth of stock.

Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up

Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. Wolkin

Price target increased by 13% to CA$17.90

New major risk - Earnings quality

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025

We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable

Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025

Investor sentiment improves as stock rises 20%

Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025

Price target decreased by 7.0% to CA$15.65

Lead Independent Director exercised options and sold CA$64k worth of stock

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025

Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Investor sentiment deteriorates as stock falls 15%

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 7.4% to CA$17.37

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus revenue estimates increase by 37%

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Investor sentiment improves as stock rises 27%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 53%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock.

Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold CA$61k worth of stock

Price target increased to CA$4.13